Passage Bio Inc Total Liabilities
Passage Bio Inc total liabilities. Based on the latest financial reports, Passage Bio Inc (PASG) has total liabilities worth $20.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PASG cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Passage Bio Inc (2018–2025)
Total liabilities of Passage Bio Inc from 2018 to 2025. This chart illustrates how Passage Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Passage Bio Inc Competitors by Total Liabilities
The table below lists competitors of Passage Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GreenOak Spain Holdings SOCIMI S.A.
MC:YGO2
|
Spain | €32.57 Million |
|
Nusantara Almazia
JK:NZIA
|
Indonesia | Rp87.37 Billion |
|
Thunderbird Resources Ltd
AU:THB
|
Australia | AU$2.48 Million |
|
WIN Metals Ltd
AU:WIN
|
Australia | AU$3.69 Million |
|
Vroom, Inc.
NASDAQ:VRMMQ
|
USA | $1.10 Billion |
|
Seyitler Kimya Sanayi AS
IS:SEYKM
|
Turkey | TL60.64 Million |
|
Trailbreaker Resources Ltd
V:TBK
|
Canada | CA$268.94K |
Liability Composition Analysis (2018–2025)
This chart breaks down Passage Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Passage Bio Inc's balance sheet.
Liquidity & Leverage Metrics
Passage Bio Inc Total Liabilities Ratios Explained
Passage Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Passage Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Passage Bio Inc (2018–2025)
The table below shows the annual total liabilities of Passage Bio Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.53 Million | +5.77% |
| 2024-12-31 | $41.15 Million | +4.81% |
| 2023-12-31 | $39.26 Million | -6.92% |
| 2022-12-31 | $42.18 Million | +15.83% |
| 2021-12-31 | $36.42 Million | +56.35% |
| 2020-12-31 | $23.29 Million | +446.66% |
| 2019-12-31 | $4.26 Million | -90.66% |
| 2018-12-31 | $45.63 Million | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more